Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Moodys
Johnson and Johnson
McKinsey
Mallinckrodt

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Patent: 8,513,390

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,513,390
Title:Modified antibody compositions, methods of making and using thereof
Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.
Inventor(s): Stagliano; Nancy E. (Santa Barbara, CA), West; James W. (Santa Barbara, CA), Kamath; Kathryn (Santa Barbara, CA), Bessette; Paul H. (Camarillo, CA), Gluck; Fred (Santa Barbara, CA), Sagert; Jason (Santa Barbara, CA), Daugherty; Patrick (Santa Barbara, CA)
Assignee: CytomX Therapeutics, Inc. (South San Francisco, CA)
Application Number:13/455,924
Patent Claims:see list of patent claims

Details for Patent 8,513,390

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial CytomX Therapeutics, Inc. (South San Francisco, CA) 2029-01-12 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial CytomX Therapeutics, Inc. (South San Francisco, CA) 2029-01-12 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial CytomX Therapeutics, Inc. (South San Francisco, CA) 2029-01-12 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial CytomX Therapeutics, Inc. (South San Francisco, CA) 2029-01-12 RX Orphan search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 003 1978-01-16   Start Trial CytomX Therapeutics, Inc. (South San Francisco, CA) 2029-01-12 DISCN search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Merck
AstraZeneca
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.